Veracyte (VCYT) Accumulated Expenses (2012 - 2026)

Veracyte has reported Accumulated Expenses for 15 years, with the latest figure at $47.7 million in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $47.7 million, up 9.08% year-over-year; the trailing twelve-month figure through Jun 2026 was $47.7 million (up 9.08% YoY), and the FY2025 annual result was $48.8 million, up 11.35% from the prior year.
• Accumulated Expenses rose to $47.7 million in Q2 2026, from $43.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $48.8 million in Q4 2025 and troughed at $30.3 million in Q1 2024.
• A 5-year average of $39.4 million and a median of $38.5 million in 2022 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses jumped 137.13%; it then dropped 20.5% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $37.8 million in 2022, then advanced by 1.73% to $38.4 million in 2023, then rose by 14.05% to $43.8 million in 2024, then rose by 11.35% to $48.8 million in 2025, then dropped by 2.3% to $47.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $47.7 million in Q2 2026, $43.1 million in Q1 2026, and $48.8 million in Q4 2025.